Eminent Drugs Private Limited - Company Profile

It is a chemicals private limited company based in Hyderabad, Telangana, India, established in 2007.
2007 Hyderabad, Telangana, India Struck Off
Last Updated:
Access Report
About Eminent Drugs Private Limited

Eminent Drugs Private Limited, a struck off private limited company, was established on 16 October 2007 in Hyderabad, Telangana, India. Engaging in manufacturing within the chemicals sector, it holds CIN: U24232TG2007PTC055931. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹0.50 M.

Its leadership includes Bhaskara Rao Setti (Director), Sharif Meera Shaik (Director), Masood Mohiddin (Director). It is based at Flat No. 416, Seshadri 7 Hills Nizampet Road, Hydernagar, Hyderabad, Telangana, 500072.

Company Details
  • Email
    **********
  • Telephone

    +91-XXXXXXXXXX

  • Website
    **********
  • Social Media
    **********
  • Apps
    **********

Company Details

  • CIN/LLPIN

    U24232TG2007PTC055931

  • Registration Number

    055931

  • Incorporation Date

    16 October 2007

  • Authorized Capital

    ₹0.50 M

  • ROC Code

    Roc Hyderabad

  • Listing Status

    Unlisted

  • Company Status

    Struck Off

Key Metrics
  • Authorised Capital ₹ 0.50 M
  • Company Age 18 Year, 4 Months
Company report

Eminent Drugs Private Limited

Company Report FY 2025-2026

Comprehensive Company Insights

Explore comprehensive insights into Eminent Drugs Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.

Access Report
Who are the key members and board of directors at Eminent Drugs Private Limited?
Current Directors
Name Designation Appointment Date Status
Bhaskara Rao Setti Director 16 Oct 2007 Current
Sharif Meera Shaik Director 16 Oct 2007 Current
Masood Mohiddin Director 16 Oct 2007 Current
Ravi Kumar Lavu Director 16 Oct 2007 Current
Satyanarayana Murthy Gopaladasu Director 16 Oct 2007 Current

Discover detailed profiles of directors and KMP - Unlock leadership insights today!

Financial Performance of Eminent Drugs.

Enhance accessibility to Eminent Drugs's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.

Eminent Drugs revenue growth over time
Eminent Drugs profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors
Emtek
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
Jan, 2021 Amount Post-IPO - Grab Valuation

investors
Hana Financial Group , GGV Capital
Feb, 2021 Amount Post-IPO - Grab Valuation

investors
Signite Partners
  • Key Matrics
  • Balance Sheet
  • Profit and Loss
  • Cash Flow
  • Ratios
Metrics
(FY 2023) YOY Growth
(FY 2022) (FY 2021) (FY 2020) (FY 2019)
Total Revenue
********
*******
*******
*******
*******
*******
Revenue from Operations
*******
*******
*******
*******
*******
*******
Total Assets
*******
*******
*******
*******
*******
*******
Profit or Loss
*******
*******
*******
*******
*******
*******
Net Worth
*******
*******
*******
*******
*******
*******
EBITDA
*******
*******
*******
*******
*******
*******

Discover detailed financial data and - Unlock financial today!

What is the Ownership and Shareholding Structure of Eminent Drugs?

Unlock access to Eminent Drugs's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.

Shareholding Pattern (FY 2024)
shareholding
  • Promoters: 92.83%
  • Public: 4.10%
  • Others: 3.07%
Shareholding Pattern over the Year
FY (2024) FY (2023) FY (2022) FY (2021) FY (2020)
Promoters 92.83 94.62 94.55 94.55 94.55
Public 4.10 3.89 3.95 3.96 3.98
Others 3.07 1.49 1.50 1.49 1.47

Reveal ownership structures and financial performance - Get instant access now!

How Many Employees Work at Eminent Drugs?

Unlock and access historical data on people associated with Eminent Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.

Employee Date Number of Employees
2020 78,000
2021 80,500
2022 83,200
2023 86,000
2024 89,500
2025 92,000
Deals i
Graph showing company valuation over time

Gain comprehensive insights into the Deals and Valuation data of Eminent Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eminent Drugs's trajectory.

Rating
Graph displaying rating trends over time

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.

Alerts
Alert Indicator

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.

Explore deal ratings and alerts - Get instant access now!

Latest Updates, News, and FAQs on Eminent Drugs
Recent Activity within the Organization
  • Director Appointment

    Progress on Bhaskara Rao Setti was appointed as a Director was appointed as a Director on 16 Oct 2007 & has been associated with this company since 18 years 4 months . was documented.

  • Director Appointment

    Sharif Meera Shaik was appointed as a Director was appointed as a Director on 16 Oct 2007 & has been associated with this company since 18 years 4 months . was recorded as a recent event.

  • Director Appointment

    The activity Masood Mohiddin was appointed as a Director was appointed as a Director on 16 Oct 2007 & has been associated with this company since 18 years 4 months . was completed.

  • Director Appointment

    Ravi Kumar Lavu was appointed as a Director was appointed as a Director on 16 Oct 2007 & has been associated with this company since 18 years 4 months . was recorded as a recent event.

  • Director Appointment

    The activity Satyanarayana Murthy Gopaladasu was appointed as a Director was appointed as a Director on 16 Oct 2007 & has been associated with this company since 18 years 4 months . was completed.

  • Company Incorporation

    The activity Eminent Drugs Private Limited was registered on 16 Oct 2007 with Roc Hyderabad & aged 18 years 4 months as per MCA records. was completed.

Explore recent activity and updates - View Recent Activity

Frequently Asked Questions
What is the CIN of Eminent Drugs Private Limited?

The CIN of Eminent Drugs Private Limited is U24232TG2007PTC055931.

Where is Eminent Drugs Private Limited headquartered?

Eminent Drugs Private Limited is headquartered at Flat No. 416, Seshadri 7 Hills Nizampet Road, Hydernagar, Hyderabad, Telangana, 500072.

When was Eminent Drugs Private Limited incorporated?

Eminent Drugs Private Limited was incorporated on 16 October 2007.

Who are the current directors of Eminent Drugs Private Limited?

The current directors of Eminent Drugs Private Limited are

What is the primary industry of Eminent Drugs Private Limited?

The primary industry of Eminent Drugs Private Limited is Chemicals.

Is Eminent Drugs Private Limited a listed company?

Eminent Drugs Private Limited is unlisted.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available